Oncology Nurse Edition Advertising

Article

OverviewONCOLOGY Nurse Edition addresses the clinical and informational needs of nurses and physician assistants working in cancer care. Scheduled publication months are February, April, July and October.Regular features in the ONCOLOGY Nurse Edition include: • Case studies • Review articles • Patient information • Drug essentials • Educational tear outsAudienceONCOLOGY Nurse Edition circulates to 8,500+ oncology nurses, advance practice nurses, and physicians assistants. Click here to view our media kit/rate card.

ADVERTISING

Overview
ONCOLOGY Nurse Edition addresses the clinical and informational needs of nurses and physician assistants working in cancer care. Scheduled publication months are February, April, July and October.

Regular features in the ONCOLOGY Nurse Edition include:
• Case studies
• Review articles
• Patient information
• Drug essentials
• Educational tear outs

Audience
ONCOLOGY Nurse Edition circulates to 8,500+ oncology nurses, advance practice nurses, and physicians assistants.

Click here to view our media kit/rate card.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
1 expert is featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
5 experts are featured in this series
5 experts are featured in this series
2 experts in this video
“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.
2 experts in this video
Earlier treatment with daratumumab may be better tolerated for patients with pretreated MRD-negative multiple myeloma.
The trispecific antibody JNJ-5322 demonstrated superior efficacy vs approved agents in multiple myeloma in results shared at the 2025 EHA Congress.
Related Content